Premium
Expression of FK 506‐binding protein 51 ( FKBP 51) in Mycosis fungoides
Author(s) -
Mascolo M.,
Romano M.F.,
Ilardi G.,
Romano S.,
Baldo A.,
Scalvenzi M.,
Argenziano G.,
Merolla F.,
Russo D.,
Varricchio S.,
Pagliuca F.,
Russo M.,
Ciancia G.,
De Rosa G.,
Staibano S.
Publication year - 2018
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14614
Subject(s) - mycosis fungoides , fkbp , medicine , immunohistochemistry , real time polymerase chain reaction , cancer research , oncology , pathology , gene , biology , lymphoma , genetics
Background Mycosis fungoides ( MF ) is the major subtype of cutaneous T‐cell lymphomas ( CTCL ). It usually has a prolonged indolent clinical course with a minority of cases acquiring a more aggressive biological profile and resistance to conventional therapies, partially attributed to the persistent activation of nuclear factor‐kappa B ( NF ‐κB) pathway. In the last decade, several papers suggested an important role for the FK 506‐binding protein 51 ( FKBP 51), an immunophilin initially cloned in lymphocytes, in the control of NF ‐κB pathway in different types of human malignancies. Objectives We aimed to investigate the possible value of FKBP 51 expression as a new reliable marker of outcome in patients with MF . Methods We assessed by immunohistochemistry ( IHC ) FKBP 51 expression in 44 patients with MF , representative of different stages of the disease. Immunohistochemical results were subsequently confirmed at mRNA level with quantitative PCR ( qPCR ) in a subset of enrolled patients. In addition, IHC and qPCR served to study the expression of some NF ‐κB‐target genes, including the tumour necrosis factor receptor‐associated factor 2 (TRAF2). Results Our results show that FKBP 51 was expressed in all evaluated cases, with the highest level of expression characterizing MF s with the worst prognosis. Moreover, a significant correlation subsisted between FKBP 51 and TRAF 2 IHC expression scores. Conclusions We hypothesize a role for FKBP 51 as a prognostic marker for MF and suggest an involvement of this immunophilin in deregulated NF ‐κB pathway of this CTCL .